Study will assess the safety, neutralizing activity and efficacy of AZD3152 in adults with conditions increasing risk of inadequate protective immune response after vaccination and thus are at high risk of developing severe COVID-19

Trial Identifier:	AZ-RU-00002
Sponsor:	AstraZeneca
Start Date:	September 2023
Primary Completion Date:	May 2024
Study Completion Date:	May 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description
	English Version
	Russian Translation

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
RU	Moscow, RU, 125284
RU	Moscow, RU, 142770
RU	Moscow, RU, 123182
RU	Moscow, RU, 115522
RU	Moscow, RU, 115478
RU	St Petersburg, RU, 197341

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company